UbiVac focuses on immuno-oncology. Its lead product is DPV-001 (DRibble), a first-in-class dendritic cell (DC)-targeted…
Biospace.com, February 18, 2016
Having outgrown its space at Providence Cancer Center, UbiVac’s leaders were evaluating other options, including a possible move to San Diego or the San Francisco Bay Area.
Portland Business Journal, Health Care Inc. Northwest, February 17, 2016
UbiVac is in active discussions with potential partners and hopes to have at least one collaborative partnership in place by early 2016 for its vaccine DPV001, said CEO Bernard Fox …
BIOPHARM INSIGHT, October 7, 2015
The vaccine, called DPV-001, stimulates a patient’s own immune system in the fight against invading tumors. It’s designed for patients who have gone through other treatment…
Portland Business Journal, September 11, 2015
Providence Cancer Center has embarked on a new lung cancer vaccine trial encompassing multiple sites around the country, including the Mayo Clinic.
Portland Business Journal, September 1, 2015